- Home
- EHGO vs OCUP Comparison
EHGO vs OCUP Comparison
Compare EHGO & OCUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHGO
- OCUP
- Stock Information
- Founded
- EHGO 2015
- OCUP 2018
- Country
- EHGO China
- OCUP United States
- Employees
- EHGO N/A
- OCUP N/A
- Industry
- EHGO
- OCUP Biotechnology: Pharmaceutical Preparations
- Sector
- EHGO
- OCUP Health Care
- Exchange
- EHGO NYSE
- OCUP Nasdaq
- Market Cap
- EHGO 47.8M
- OCUP 53.1M
- IPO Year
- EHGO 2024
- OCUP N/A
- Fundamental
- Price
- EHGO $1.98
- OCUP $1.32
- Analyst Decision
- EHGO
- OCUP Strong Buy
- Analyst Count
- EHGO 0
- OCUP 3
- Target Price
- EHGO N/A
- OCUP $18.67
- AVG Volume (30 Days)
- EHGO 8.7K
- OCUP 86.6K
- Earning Date
- EHGO 11-15-2024
- OCUP 11-11-2024
- Dividend Yield
- EHGO N/A
- OCUP N/A
- EPS Growth
- EHGO N/A
- OCUP N/A
- EPS
- EHGO 0.00
- OCUP N/A
- Revenue
- EHGO $16,963,957.00
- OCUP $16,449,000.00
- Revenue This Year
- EHGO N/A
- OCUP N/A
- Revenue Next Year
- EHGO N/A
- OCUP $258.69
- P/E Ratio
- EHGO $4,974.03
- OCUP N/A
- Revenue Growth
- EHGO N/A
- OCUP N/A
- 52 Week Low
- EHGO $1.45
- OCUP $1.15
- 52 Week High
- EHGO $4.40
- OCUP $3.53
- Technical
- Relative Strength Index (RSI)
- EHGO N/A
- OCUP 48.70
- Support Level
- EHGO N/A
- OCUP $1.25
- Resistance Level
- EHGO N/A
- OCUP $1.35
- Average True Range (ATR)
- EHGO 0.00
- OCUP 0.08
- MACD
- EHGO 0.00
- OCUP 0.01
- Stochastic Oscillator
- EHGO 0.00
- OCUP 29.17
About EHGO ESHALLGO INC
Eshallgo Inc. focuses on two distinct market sectors: office supply sale and leasing, and after-sale maintenance and repair. It is an authorized distributor of brands of office equipment, including HP, Epson, Xerox, Sharp, Toshiba, Konica, Kyocera, and other brands.
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.